Trending Now
Protalix BioTherapeutics Inc. (NYSEAMERICAN: PLX) Reports 36% Revenue Growth In Q3...
Protalix BioTherapeutics Inc. (NYSEAMERICAN: PLX) has announced Q3 2021 financial results and offered an update on the latest clinical, regulatory and corporate developments.
Updates on...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Ovid Therapeutics Inc (NASDAQ:OVID) Discloses Findings From Its ARCADE and ENDYMION...
Ovid Therapeutics Inc (NASDAQ:OVID) recently announced the results of its ARCADE and ENDYMION studies evaluating its pipeline drug soticlestat as a potential therapy for...
MAKE IT MODERN
LATEST REVIEWS
Alexion (NASDAQ:ALXN) Receives FDA Approval For ULTOMIRIS® 100 mg/mL Formulation In...
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) has received approval from the US FDA for ULTOMIRIS® (ravlizumab-cwvz) 100mg/mL formulation.
ULTOMIRIS® can reduce the time spent to receive treatment...
MAKE IT MODERN
PERFORMANCE TRAINING
Vaxart Inc. (NASDAQ: VXRT) Receives FDA Approval For its IND for S-Only SARS-CoV-2...
Vaxart Inc. (NASDAQ: VXRT) has received US FDA clearance for its Investigational New Drug application for its S-only oral COVID-19 vaccine candidate. The vaccine...
Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
Biotech stocks have been hammered back to back for two years in a row now. The last time the SPDR ETF suffered...
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) Enters a Note Purchase Agreement And Prices $35 Million...
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) has entered a note purchase agreement with Athyrium Capital Management-managed funds for around $100 million senior secured notes.
Financing offers...
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Presents Clinical study Data of Lifileucel Combination with Pembrolizumab...
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) has announced clinical data from the study of lifileucel combined with pembrolizumab in advanced cancers at the annual Society...
Cingulate Surges (CING) on New European Patent for ADHD Treatment and promising further advancements
Cingulate Inc. (NASDAQ: CING), a pioneer in biopharmaceuticals, announced a significant breakthrough with the issuance of a European patent for its leading...
MAKE IT MODERN
